Canada Markets closed

Acerus Pharmaceuticals Corporation (ASP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.04000.0000 (0.00%)
At close: 01:46PM EST
Full screen
Previous Close0.0350
Open0.0350
Bid0.0350 x N/A
Ask0.0400 x N/A
Day's Range0.0350 - 0.0400
52 Week Range0.0300 - 0.0700
Volume1,241,565
Avg. Volume131,347
Market Cap61.504M
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0370
Earnings DateMar. 09, 2022 - Mar. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Baystreet

    Stocks in play: Acerus Pharmaceuticals Corporation

    Announced the signing of an agreement with Verity Pharmaceuticals for the exclusive rights to promote ...

  • GlobeNewswire

    Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico

    Verity Pharmaceuticals will begin promoting NATESTO to health care professionals throughout Puerto Rico in Q1, 2022. This agreement represents a new partnership and the continued expansion of NATESTO into new markets. TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the signing of an agreement with Verity Pharmaceuticals (“Verity Pharma”) for the exclusive rights to promote NATESTO in Puerto Rico. Ver

  • GlobeNewswire

    Acerus Announces Amendments to Loan Facilities

    TORONTO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase the existing subordinated secured loan facility (the “Loan Facility”) from US$15 million to US$25 million. This increase will be made available to the Company by